nodes	percent_of_prediction	percent_of_DWPC	metapath
Tobramycin—Dry skin—Prednisone—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Tobramycin—Nausea—Pentoxifylline—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Tobramycin—Malaise—Lisinopril—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Tobramycin—Vertigo—Lisinopril—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Tobramycin—Diarrhoea—Mometasone—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Tobramycin—Hypokalaemia—Prednisone—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Tobramycin—Leukopenia—Lisinopril—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Tobramycin—Renal failure acute—Methotrexate—systemic scleroderma	0.00102	0.00102	CcSEcCtD
Tobramycin—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Tobramycin—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.00101	0.00101	CcSEcCtD
Tobramycin—Skin disorder—Mycophenolic acid—systemic scleroderma	0.001	0.001	CcSEcCtD
Tobramycin—Dermatitis exfoliative—Methotrexate—systemic scleroderma	0.000994	0.000994	CcSEcCtD
Tobramycin—Cough—Lisinopril—systemic scleroderma	0.000993	0.000993	CcSEcCtD
Tobramycin—Muscular weakness—Prednisone—systemic scleroderma	0.00099	0.00099	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000988	0.000988	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000985	0.000985	CcSEcCtD
Tobramycin—Anorexia—Mycophenolic acid—systemic scleroderma	0.000983	0.000983	CcSEcCtD
Tobramycin—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000976	0.000976	CcSEcCtD
Tobramycin—Paraesthesia—Leflunomide—systemic scleroderma	0.000971	0.000971	CcSEcCtD
Tobramycin—Chest pain—Lisinopril—systemic scleroderma	0.000969	0.000969	CcSEcCtD
Tobramycin—Myalgia—Lisinopril—systemic scleroderma	0.000969	0.000969	CcSEcCtD
Tobramycin—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000964	0.000964	CcSEcCtD
Tobramycin—Dyspnoea—Leflunomide—systemic scleroderma	0.000964	0.000964	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000962	0.000962	CcSEcCtD
Tobramycin—Discomfort—Lisinopril—systemic scleroderma	0.000957	0.000957	CcSEcCtD
Tobramycin—Lethargy—Methotrexate—systemic scleroderma	0.000957	0.000957	CcSEcCtD
Tobramycin—Vomiting—Mometasone—systemic scleroderma	0.000949	0.000949	CcSEcCtD
Tobramycin—Feeling abnormal—Azathioprine—systemic scleroderma	0.000943	0.000943	CcSEcCtD
Tobramycin—Rash—Mometasone—systemic scleroderma	0.000941	0.000941	CcSEcCtD
Tobramycin—Asthenia—Captopril—systemic scleroderma	0.000941	0.000941	CcSEcCtD
Tobramycin—Dermatitis—Mometasone—systemic scleroderma	0.000941	0.000941	CcSEcCtD
Tobramycin—Decreased appetite—Leflunomide—systemic scleroderma	0.00094	0.00094	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000939	0.000939	CcSEcCtD
Tobramycin—Confusional state—Lisinopril—systemic scleroderma	0.000936	0.000936	CcSEcCtD
Tobramycin—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000936	0.000936	CcSEcCtD
Tobramycin—Headache—Mometasone—systemic scleroderma	0.000935	0.000935	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000933	0.000933	CcSEcCtD
Tobramycin—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000929	0.000929	CcSEcCtD
Tobramycin—Pruritus—Captopril—systemic scleroderma	0.000928	0.000928	CcSEcCtD
Tobramycin—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000926	0.000926	CcSEcCtD
Tobramycin—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000925	0.000925	CcSEcCtD
Tobramycin—Pain—Leflunomide—systemic scleroderma	0.000924	0.000924	CcSEcCtD
Tobramycin—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000922	0.000922	CcSEcCtD
Tobramycin—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000919	0.000919	CcSEcCtD
Tobramycin—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000911	0.000911	CcSEcCtD
Tobramycin—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000909	0.000909	CcSEcCtD
Tobramycin—Abdominal pain—Azathioprine—systemic scleroderma	0.000905	0.000905	CcSEcCtD
Tobramycin—Body temperature increased—Azathioprine—systemic scleroderma	0.000905	0.000905	CcSEcCtD
Tobramycin—Skin disorder—Lisinopril—systemic scleroderma	0.000902	0.000902	CcSEcCtD
Tobramycin—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000899	0.000899	CcSEcCtD
Tobramycin—Diarrhoea—Captopril—systemic scleroderma	0.000897	0.000897	CcSEcCtD
Tobramycin—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000896	0.000896	CcSEcCtD
Tobramycin—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000896	0.000896	CcSEcCtD
Tobramycin—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000892	0.000892	CcSEcCtD
Tobramycin—Feeling abnormal—Leflunomide—systemic scleroderma	0.000891	0.000891	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00089	0.00089	CcSEcCtD
Tobramycin—Nausea—Mometasone—systemic scleroderma	0.000887	0.000887	CcSEcCtD
Tobramycin—Anorexia—Lisinopril—systemic scleroderma	0.000885	0.000885	CcSEcCtD
Tobramycin—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000884	0.000884	CcSEcCtD
Tobramycin—Pain—Mycophenolic acid—systemic scleroderma	0.000882	0.000882	CcSEcCtD
Tobramycin—Weight decreased—Prednisone—systemic scleroderma	0.000878	0.000878	CcSEcCtD
Tobramycin—Cough—Mycophenolate mofetil—systemic scleroderma	0.00087	0.00087	CcSEcCtD
Tobramycin—Dizziness—Captopril—systemic scleroderma	0.000867	0.000867	CcSEcCtD
Tobramycin—Urticaria—Leflunomide—systemic scleroderma	0.000859	0.000859	CcSEcCtD
Tobramycin—Abdominal pain—Leflunomide—systemic scleroderma	0.000854	0.000854	CcSEcCtD
Tobramycin—Body temperature increased—Leflunomide—systemic scleroderma	0.000854	0.000854	CcSEcCtD
Tobramycin—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00085	0.00085	CcSEcCtD
Tobramycin—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000849	0.000849	CcSEcCtD
Tobramycin—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000849	0.000849	CcSEcCtD
Tobramycin—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000848	0.000848	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000846	0.000846	CcSEcCtD
Tobramycin—Hypersensitivity—Azathioprine—systemic scleroderma	0.000843	0.000843	CcSEcCtD
Tobramycin—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000843	0.000843	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000843	0.000843	CcSEcCtD
Tobramycin—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000839	0.000839	CcSEcCtD
Tobramycin—Paraesthesia—Lisinopril—systemic scleroderma	0.000834	0.000834	CcSEcCtD
Tobramycin—Vomiting—Captopril—systemic scleroderma	0.000834	0.000834	CcSEcCtD
Tobramycin—Dyspnoea—Lisinopril—systemic scleroderma	0.000828	0.000828	CcSEcCtD
Tobramycin—Rash—Captopril—systemic scleroderma	0.000827	0.000827	CcSEcCtD
Tobramycin—Dermatitis—Captopril—systemic scleroderma	0.000826	0.000826	CcSEcCtD
Tobramycin—Headache—Captopril—systemic scleroderma	0.000822	0.000822	CcSEcCtD
Tobramycin—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.00082	0.00082	CcSEcCtD
Tobramycin—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000815	0.000815	CcSEcCtD
Tobramycin—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000815	0.000815	CcSEcCtD
Tobramycin—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000814	0.000814	CcSEcCtD
Tobramycin—Asthma—Methotrexate—systemic scleroderma	0.000811	0.000811	CcSEcCtD
Tobramycin—Decreased appetite—Lisinopril—systemic scleroderma	0.000807	0.000807	CcSEcCtD
Tobramycin—Eosinophilia—Methotrexate—systemic scleroderma	0.000803	0.000803	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000802	0.000802	CcSEcCtD
Tobramycin—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000798	0.000798	CcSEcCtD
Tobramycin—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000797	0.000797	CcSEcCtD
Tobramycin—Hypersensitivity—Leflunomide—systemic scleroderma	0.000796	0.000796	CcSEcCtD
Tobramycin—Pain—Lisinopril—systemic scleroderma	0.000794	0.000794	CcSEcCtD
Tobramycin—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00079	0.00079	CcSEcCtD
Tobramycin—Diarrhoea—Azathioprine—systemic scleroderma	0.000783	0.000783	CcSEcCtD
Tobramycin—Nausea—Captopril—systemic scleroderma	0.000779	0.000779	CcSEcCtD
Tobramycin—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000776	0.000776	CcSEcCtD
Tobramycin—Asthenia—Leflunomide—systemic scleroderma	0.000775	0.000775	CcSEcCtD
Tobramycin—Feeling abnormal—Lisinopril—systemic scleroderma	0.000765	0.000765	CcSEcCtD
Tobramycin—Pruritus—Leflunomide—systemic scleroderma	0.000765	0.000765	CcSEcCtD
Tobramycin—Connective tissue disorder—Prednisone—systemic scleroderma	0.000763	0.000763	CcSEcCtD
Tobramycin—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000759	0.000759	CcSEcCtD
Tobramycin—Dizziness—Azathioprine—systemic scleroderma	0.000757	0.000757	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000753	0.000753	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000741	0.000741	CcSEcCtD
Tobramycin—Asthenia—Mycophenolic acid—systemic scleroderma	0.00074	0.00074	CcSEcCtD
Tobramycin—Diarrhoea—Leflunomide—systemic scleroderma	0.00074	0.00074	CcSEcCtD
Tobramycin—Urticaria—Lisinopril—systemic scleroderma	0.000738	0.000738	CcSEcCtD
Tobramycin—Abdominal pain—Lisinopril—systemic scleroderma	0.000734	0.000734	CcSEcCtD
Tobramycin—Body temperature increased—Lisinopril—systemic scleroderma	0.000734	0.000734	CcSEcCtD
Tobramycin—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000731	0.000731	CcSEcCtD
Tobramycin—Pruritus—Mycophenolic acid—systemic scleroderma	0.000729	0.000729	CcSEcCtD
Tobramycin—Vomiting—Azathioprine—systemic scleroderma	0.000728	0.000728	CcSEcCtD
Tobramycin—Eye disorder—Prednisone—systemic scleroderma	0.000726	0.000726	CcSEcCtD
Tobramycin—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000725	0.000725	CcSEcCtD
Tobramycin—Infestation NOS—Methotrexate—systemic scleroderma	0.000723	0.000723	CcSEcCtD
Tobramycin—Infestation—Methotrexate—systemic scleroderma	0.000723	0.000723	CcSEcCtD
Tobramycin—Rash—Azathioprine—systemic scleroderma	0.000722	0.000722	CcSEcCtD
Tobramycin—Dermatitis—Azathioprine—systemic scleroderma	0.000721	0.000721	CcSEcCtD
Tobramycin—Headache—Azathioprine—systemic scleroderma	0.000717	0.000717	CcSEcCtD
Tobramycin—Dizziness—Leflunomide—systemic scleroderma	0.000715	0.000715	CcSEcCtD
Tobramycin—Renal failure—Methotrexate—systemic scleroderma	0.00071	0.00071	CcSEcCtD
Tobramycin—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000707	0.000707	CcSEcCtD
Tobramycin—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000705	0.000705	CcSEcCtD
Tobramycin—Stomatitis—Methotrexate—systemic scleroderma	0.000705	0.000705	CcSEcCtD
Tobramycin—Angiopathy—Prednisone—systemic scleroderma	0.000704	0.000704	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000703	0.000703	CcSEcCtD
Tobramycin—Immune system disorder—Prednisone—systemic scleroderma	0.000701	0.000701	CcSEcCtD
Tobramycin—Pain—Mycophenolate mofetil—systemic scleroderma	0.000696	0.000696	CcSEcCtD
Tobramycin—Vomiting—Leflunomide—systemic scleroderma	0.000687	0.000687	CcSEcCtD
Tobramycin—Hypersensitivity—Lisinopril—systemic scleroderma	0.000684	0.000684	CcSEcCtD
Tobramycin—Dizziness—Mycophenolic acid—systemic scleroderma	0.000682	0.000682	CcSEcCtD
Tobramycin—Epistaxis—Methotrexate—systemic scleroderma	0.000682	0.000682	CcSEcCtD
Tobramycin—Rash—Leflunomide—systemic scleroderma	0.000681	0.000681	CcSEcCtD
Tobramycin—Dermatitis—Leflunomide—systemic scleroderma	0.000681	0.000681	CcSEcCtD
Tobramycin—Nausea—Azathioprine—systemic scleroderma	0.00068	0.00068	CcSEcCtD
Tobramycin—Headache—Leflunomide—systemic scleroderma	0.000677	0.000677	CcSEcCtD
Tobramycin—Erythema—Prednisone—systemic scleroderma	0.000676	0.000676	CcSEcCtD
Tobramycin—Agranulocytosis—Methotrexate—systemic scleroderma	0.000674	0.000674	CcSEcCtD
Tobramycin—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000671	0.000671	CcSEcCtD
Tobramycin—Asthenia—Lisinopril—systemic scleroderma	0.000666	0.000666	CcSEcCtD
Tobramycin—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000665	0.000665	CcSEcCtD
Tobramycin—Pruritus—Lisinopril—systemic scleroderma	0.000657	0.000657	CcSEcCtD
Tobramycin—Vomiting—Mycophenolic acid—systemic scleroderma	0.000656	0.000656	CcSEcCtD
Tobramycin—Rash—Mycophenolic acid—systemic scleroderma	0.00065	0.00065	CcSEcCtD
Tobramycin—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00065	0.00065	CcSEcCtD
Tobramycin—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000646	0.000646	CcSEcCtD
Tobramycin—Headache—Mycophenolic acid—systemic scleroderma	0.000646	0.000646	CcSEcCtD
Tobramycin—Pharyngitis—Methotrexate—systemic scleroderma	0.000644	0.000644	CcSEcCtD
Tobramycin—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000643	0.000643	CcSEcCtD
Tobramycin—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000643	0.000643	CcSEcCtD
Tobramycin—Nausea—Leflunomide—systemic scleroderma	0.000642	0.000642	CcSEcCtD
Tobramycin—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000641	0.000641	CcSEcCtD
Tobramycin—Vision blurred—Prednisone—systemic scleroderma	0.000637	0.000637	CcSEcCtD
Tobramycin—Urethral disorder—Methotrexate—systemic scleroderma	0.000636	0.000636	CcSEcCtD
Tobramycin—Diarrhoea—Lisinopril—systemic scleroderma	0.000635	0.000635	CcSEcCtD
Tobramycin—Ill-defined disorder—Prednisone—systemic scleroderma	0.000627	0.000627	CcSEcCtD
Tobramycin—Visual impairment—Methotrexate—systemic scleroderma	0.000625	0.000625	CcSEcCtD
Tobramycin—Anaemia—Prednisone—systemic scleroderma	0.000625	0.000625	CcSEcCtD
Tobramycin—Angioedema—Prednisone—systemic scleroderma	0.000618	0.000618	CcSEcCtD
Tobramycin—Dizziness—Lisinopril—systemic scleroderma	0.000614	0.000614	CcSEcCtD
Tobramycin—Nausea—Mycophenolic acid—systemic scleroderma	0.000612	0.000612	CcSEcCtD
Tobramycin—Malaise—Prednisone—systemic scleroderma	0.000609	0.000609	CcSEcCtD
Tobramycin—Vertigo—Prednisone—systemic scleroderma	0.000607	0.000607	CcSEcCtD
Tobramycin—Eye disorder—Methotrexate—systemic scleroderma	0.000606	0.000606	CcSEcCtD
Tobramycin—Tinnitus—Methotrexate—systemic scleroderma	0.000605	0.000605	CcSEcCtD
Tobramycin—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.0006	0.0006	CcSEcCtD
Tobramycin—Vomiting—Lisinopril—systemic scleroderma	0.00059	0.00059	CcSEcCtD
Tobramycin—Angiopathy—Methotrexate—systemic scleroderma	0.000589	0.000589	CcSEcCtD
Tobramycin—Immune system disorder—Methotrexate—systemic scleroderma	0.000586	0.000586	CcSEcCtD
Tobramycin—Rash—Lisinopril—systemic scleroderma	0.000586	0.000586	CcSEcCtD
Tobramycin—Dermatitis—Lisinopril—systemic scleroderma	0.000585	0.000585	CcSEcCtD
Tobramycin—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000585	0.000585	CcSEcCtD
Tobramycin—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000584	0.000584	CcSEcCtD
Tobramycin—Headache—Lisinopril—systemic scleroderma	0.000582	0.000582	CcSEcCtD
Tobramycin—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000576	0.000576	CcSEcCtD
Tobramycin—Myalgia—Prednisone—systemic scleroderma	0.000575	0.000575	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000571	0.000571	CcSEcCtD
Tobramycin—Discomfort—Prednisone—systemic scleroderma	0.000568	0.000568	CcSEcCtD
Tobramycin—Erythema—Methotrexate—systemic scleroderma	0.000565	0.000565	CcSEcCtD
Tobramycin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000557	0.000557	CcSEcCtD
Tobramycin—Dysgeusia—Methotrexate—systemic scleroderma	0.000553	0.000553	CcSEcCtD
Tobramycin—Nausea—Lisinopril—systemic scleroderma	0.000552	0.000552	CcSEcCtD
Tobramycin—Anaphylactic shock—Prednisone—systemic scleroderma	0.000552	0.000552	CcSEcCtD
Tobramycin—Back pain—Methotrexate—systemic scleroderma	0.000546	0.000546	CcSEcCtD
Tobramycin—Nervous system disorder—Prednisone—systemic scleroderma	0.000541	0.000541	CcSEcCtD
Tobramycin—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000538	0.000538	CcSEcCtD
Tobramycin—Skin disorder—Prednisone—systemic scleroderma	0.000536	0.000536	CcSEcCtD
Tobramycin—Vision blurred—Methotrexate—systemic scleroderma	0.000532	0.000532	CcSEcCtD
Tobramycin—Anorexia—Prednisone—systemic scleroderma	0.000526	0.000526	CcSEcCtD
Tobramycin—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000524	0.000524	CcSEcCtD
Tobramycin—Anaemia—Methotrexate—systemic scleroderma	0.000522	0.000522	CcSEcCtD
Tobramycin—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000517	0.000517	CcSEcCtD
Tobramycin—Rash—Mycophenolate mofetil—systemic scleroderma	0.000513	0.000513	CcSEcCtD
Tobramycin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000513	0.000513	CcSEcCtD
Tobramycin—Headache—Mycophenolate mofetil—systemic scleroderma	0.00051	0.00051	CcSEcCtD
Tobramycin—Malaise—Methotrexate—systemic scleroderma	0.000509	0.000509	CcSEcCtD
Tobramycin—Vertigo—Methotrexate—systemic scleroderma	0.000507	0.000507	CcSEcCtD
Tobramycin—Leukopenia—Methotrexate—systemic scleroderma	0.000506	0.000506	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000503	0.000503	CcSEcCtD
Tobramycin—Paraesthesia—Prednisone—systemic scleroderma	0.000495	0.000495	CcSEcCtD
Tobramycin—Cough—Methotrexate—systemic scleroderma	0.000493	0.000493	CcSEcCtD
Tobramycin—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000483	0.000483	CcSEcCtD
Tobramycin—Chest pain—Methotrexate—systemic scleroderma	0.000481	0.000481	CcSEcCtD
Tobramycin—Myalgia—Methotrexate—systemic scleroderma	0.000481	0.000481	CcSEcCtD
Tobramycin—Decreased appetite—Prednisone—systemic scleroderma	0.000479	0.000479	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000478	0.000478	CcSEcCtD
Tobramycin—Discomfort—Methotrexate—systemic scleroderma	0.000475	0.000475	CcSEcCtD
Tobramycin—Confusional state—Methotrexate—systemic scleroderma	0.000465	0.000465	CcSEcCtD
Tobramycin—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000461	0.000461	CcSEcCtD
Tobramycin—Feeling abnormal—Prednisone—systemic scleroderma	0.000455	0.000455	CcSEcCtD
Tobramycin—Nervous system disorder—Methotrexate—systemic scleroderma	0.000452	0.000452	CcSEcCtD
Tobramycin—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000451	0.000451	CcSEcCtD
Tobramycin—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000451	0.000451	CcSEcCtD
Tobramycin—Skin disorder—Methotrexate—systemic scleroderma	0.000448	0.000448	CcSEcCtD
Tobramycin—Anorexia—Methotrexate—systemic scleroderma	0.000439	0.000439	CcSEcCtD
Tobramycin—Urticaria—Prednisone—systemic scleroderma	0.000438	0.000438	CcSEcCtD
Tobramycin—Abdominal pain—Prednisone—systemic scleroderma	0.000436	0.000436	CcSEcCtD
Tobramycin—Body temperature increased—Prednisone—systemic scleroderma	0.000436	0.000436	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.00042	0.00042	CcSEcCtD
Tobramycin—Paraesthesia—Methotrexate—systemic scleroderma	0.000414	0.000414	CcSEcCtD
Tobramycin—Dyspnoea—Methotrexate—systemic scleroderma	0.000411	0.000411	CcSEcCtD
Tobramycin—Hypersensitivity—Prednisone—systemic scleroderma	0.000406	0.000406	CcSEcCtD
Tobramycin—Decreased appetite—Methotrexate—systemic scleroderma	0.000401	0.000401	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000398	0.000398	CcSEcCtD
Tobramycin—Asthenia—Prednisone—systemic scleroderma	0.000396	0.000396	CcSEcCtD
Tobramycin—Pain—Methotrexate—systemic scleroderma	0.000394	0.000394	CcSEcCtD
Tobramycin—Pruritus—Prednisone—systemic scleroderma	0.00039	0.00039	CcSEcCtD
Tobramycin—Feeling abnormal—Methotrexate—systemic scleroderma	0.00038	0.00038	CcSEcCtD
Tobramycin—Diarrhoea—Prednisone—systemic scleroderma	0.000377	0.000377	CcSEcCtD
Tobramycin—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000377	0.000377	CcSEcCtD
Tobramycin—Urticaria—Methotrexate—systemic scleroderma	0.000366	0.000366	CcSEcCtD
Tobramycin—Dizziness—Prednisone—systemic scleroderma	0.000365	0.000365	CcSEcCtD
Tobramycin—Abdominal pain—Methotrexate—systemic scleroderma	0.000364	0.000364	CcSEcCtD
Tobramycin—Body temperature increased—Methotrexate—systemic scleroderma	0.000364	0.000364	CcSEcCtD
Tobramycin—Vomiting—Prednisone—systemic scleroderma	0.000351	0.000351	CcSEcCtD
Tobramycin—Rash—Prednisone—systemic scleroderma	0.000348	0.000348	CcSEcCtD
Tobramycin—Dermatitis—Prednisone—systemic scleroderma	0.000347	0.000347	CcSEcCtD
Tobramycin—Headache—Prednisone—systemic scleroderma	0.000346	0.000346	CcSEcCtD
Tobramycin—Hypersensitivity—Methotrexate—systemic scleroderma	0.00034	0.00034	CcSEcCtD
Tobramycin—Asthenia—Methotrexate—systemic scleroderma	0.000331	0.000331	CcSEcCtD
Tobramycin—Nausea—Prednisone—systemic scleroderma	0.000328	0.000328	CcSEcCtD
Tobramycin—Pruritus—Methotrexate—systemic scleroderma	0.000326	0.000326	CcSEcCtD
Tobramycin—Diarrhoea—Methotrexate—systemic scleroderma	0.000315	0.000315	CcSEcCtD
Tobramycin—Dizziness—Methotrexate—systemic scleroderma	0.000305	0.000305	CcSEcCtD
Tobramycin—Vomiting—Methotrexate—systemic scleroderma	0.000293	0.000293	CcSEcCtD
Tobramycin—Rash—Methotrexate—systemic scleroderma	0.000291	0.000291	CcSEcCtD
Tobramycin—Dermatitis—Methotrexate—systemic scleroderma	0.00029	0.00029	CcSEcCtD
Tobramycin—Headache—Methotrexate—systemic scleroderma	0.000289	0.000289	CcSEcCtD
Tobramycin—Nausea—Methotrexate—systemic scleroderma	0.000274	0.000274	CcSEcCtD
